Bio News
A combination therapy for rare anemia developed by a research team at Soochow University in China demonstrated high efficacy in a phase 2 clinical trial, recording an overall response rate of 93% at 6 months. The regimen, which combines the immunosuppressant sirolimus with the erythropoiesis-stimulating agent roxadustat, enabled 89.5% of patients to achieve transfusion independence after 3 months of treatment. The research team confirmed the therapy’s safety, reporting that severe adverse events of grade 3 or higher occurred in only 4.9% of patients, and plans to conduct a large-scale phase 3 clinical trial in the future.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
